-Eric A Klein Researcher Activity Profile

Research Author Detailed Information 

Eric A Klein Publication Rate By Year

Eric A Klein has published 1 paper(s) in 2003, 1 paper(s) in 2005, 6 paper(s) in 2006, 12 paper(s) in 2007, 10 paper(s) in 2008, for a total of 30 research publications in total.

Eric A Ea Klein Author Information

LAST NAME: klein

FIRST NAME: Eric A

INITIALS: ea

AFFILIATION:

Papers

Eric A Klein's Publication Record

1. Nonseminomatous germ cell tumor after chemotherapy with residual mass invading the spine. Year Published: 2006
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
2. Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention. Year Published: 2006
3. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. Year Published: 2006
4. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. Year Published: 2006
5. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Year Published: 2007
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
6. The surgical learning curve for prostate cancer control after radical prostatectomy. Year Published: 2007
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. vickersa@mskcc.org
7. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. Year Published: 2007
University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA. rbmontgo@u.washington.edu
8. A new nomogram for predicting seminal vesicle invasion at radical prostatectomy. Year Published: 2007
Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH, USA. kleine@ccf.org
9. Preoperative PSA is still predictive of cancer volume and grade in late PSA era. Year Published: 2007
Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
10. How many lymphadenectomies does it take to cure one patient? Year Published: 2007
Glickman Urologic and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
11. Pathologic stage migration has slowed in the late PSA era. Year Published: 2007
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
12. A new nomogram for predicting seminal vesicle invasion at radical prostatectomy. Year Published: 2007
Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH, USA. kleine@ccf.org
13. Preoperative PSA is still predictive of cancer volume and grade in late PSA era. Year Published: 2007
Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
14. Pathologic stage migration has slowed in the late PSA era. Year Published: 2007
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
15. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. Year Published: 2007
Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri 63105, USA. kibela@wustl.edu
16. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Year Published: 2008
Department of Pharmacology and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. cfyang@spirit.gcrc.upenn.edu
17. Nonseminomatous germ cell tumor after chemotherapy with residual mass invading the spine. Year Published: 2006
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
18. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21(Cip1). Year Published: 2008
Department of Pharmacology and Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia, PA 19104, U.S.A.
19. Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Year Published: 2003
Section of Urologic Oncology, Urologic Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
20. How many lymphadenectomies does it take to cure one patient? Year Published: 2007
21. Letter from the editor. Year Published: 2008
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, A100, 9500 Euclid Avenue, Cleveland, OH 44195.
22. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Year Published: 2008
Section of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic, Cleveland, Ohio.
23. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Year Published: 2008
Section of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
24. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. Year Published: 2005
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
25. Nonseminomatous germ cell tumor after chemotherapy with residual mass invading the spine. Year Published: 2006
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
26. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Year Published: 2008
Section of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
27. Open to debate. The motion: at least 18 cores are necessary to make a prostatic biopsy useful. Year Published: 2008
28. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Year Published: 2008
Department of Pharmacology and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. cfyang@spirit.gcrc.upenn.edu
29. Inflammation, infection, and prostate cancer. Year Published: 2008
aGlickman Urologic and Kidney Institute, Cleveland, USA bDepartment of Cancer Biology, Lerner Research Institute, Cleveland, USA cTaussig Cancer Institute, Cleveland, USA dCleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio, USA
30. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Year Published: 2008
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.